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Abstract
Background/Aims: Fibulin-3, an extracellular matrix glycoprotein, inhibits vascular oxidative 
stress and remodeling in hypertension. Oxidative stress is prevalent in chronic kidney disease 
(CKD) patients and is an important mediator of osteo-/chondrogenic transdifferentiation 
and calcification of vascular smooth muscle cells (VSMCs) during hyperphosphatemia. 
Therefore, the present study explored the effects of Fibulin-3 on phosphate-induced vascular 
calcification. Methods: Experiments were performed in primary human aortic smooth muscle 
cells (HAoSMCs) treated with control or with phosphate without or with additional treatment 
with recombinant human Fibulin-3 protein or with hydrogen peroxide as an exogenous 
source of oxidative stress. Results: Treatment with calcification medium significantly increased 
calcium deposition in HAoSMCs, an effect significantly blunted by additional treatment with 
Fibulin-3. Moreover, phosphate-induced alkaline phosphatase activity and mRNA expression 
of osteogenic and chondrogenic markers MSX2, CBFA1, SOX9 and ALPL were all significantly 
reduced by addition of Fibulin-3. These effects were paralleled by similar regulation of oxidative 
stress in HAoSMCs. Phosphate treatment significantly up-regulated mRNA expression of 
the oxidative stress markers NOX4 and CYBA, down-regulated total antioxidant capacity 
and increased the expression of downstream effectors of oxidative stress PAI-1, MMP2 and 
MMP9 as well as BAX/BLC2 ratio in HAoSMCs, all effects blocked by additional treatment with 
Fibulin-3. Furthermore, the protective effects of Fibulin-3 on phosphate-induced osteogenic 
and chondrogenic markers expression in HAoSMCs were reversed by additional treatment 
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with hydrogen peroxide. Conclusions: Fibulin-3 attenuates phosphate-induced osteo-/
chondrogenic transdifferentiation and calcification of VSMCs, effects involving inhibition of 
oxidative stress. Up-regulation or supplementation of Fibulin-3 may be beneficial in reducing 
the progression of vascular calcification during hyperphosphatemic conditions such as CKD.
IntroductionFibulin-3 is an extracellular matrix protein [1, 2] widely expressed in various tissues [2] including the vasculature [1, 3]. The functions of Fibulin-3 include basement 
membrane organization and elastic fiber formation [4]. It also interacts with other matrix 
proteins, forming anchoring structures to regulate cell proliferation and migration [4, 5]. 
Furthermore, Fibulin-3 promotes angiogenesis [6]. In addition to its role in extracellular 
matrix organization, Fibulin-3 participates in various intracellular signaling pathways [4, 7-9]. 
In the media of arterial wall, Fibulin-3 expression is up-regulated at hypertensive vascular remodeling [3, 10]. Fibulin-3 has previously been suggested as an arterial growth factor [3, 6] as injection of Fibulin-3 protein increases aortic wall thickness in spontaneously hypertensive rats [10]. However, Fibulin-3 reduces systolic blood pressure and improves vascular health [10], at least in part, by reducing aortic oxidative stress [10-
12] and expression of matrix gelatinases [10, 13]. In vascular smooth muscle cells (VSMCs), 
gelatinase expression and activity are stimulated by excessive oxidative stress [14-17].Oxidative stress is commonly associated with cardiovascular disease [18, 19] and all-
cause mortality in patients with chronic kidney disease (CKD) [20]. The high cardiovascular morbidity and mortality of CKD patients is associated with medial vascular calcification [21]. 
Vascular calcification is an active process promoted by osteo-/chondrogenic reprogramming 
of VSMCs [22, 23]. Various pathological factors [22, 24-26], most importantly phosphate 
[27], induce the phenotypical transdifferentiation of contractile VSMCs into osteoblast and chondroblast-like cells via complex signaling pathways. Oxidative stress is an 
important mediator of osteo-/chondrogenic transdifferentiation of VSMCs [28-30]. These 
transdifferentiated VSMCs express osteogenic and chondrogenic transcription factors, such as 
msh homeobox 2 (MSX2), core-binding factor α-1 (CBFA1) and SRY-Box 9 (SOX9) [24, 31, 32], 
as well as osteogenic enzymes, such as tissue non-specific alkaline phosphatase (ALPL) [33] to cause an active mineralization of vascular tissue. The present study explored the effects of Fibulin-3 protein on phosphate-induced 
osteo-/chondrogenic transdifferentiation and calcification of VSMCs in-vitro as well as the possible involvement of oxidative stress suppression in mediating these effects.
Materials and Methods
Cell culture of primary human aortic smooth muscle cells
Primary human aortic smooth muscle cells (HAoSMCs) commercially obtained from 
Thermo Fisher Scientific were cultured in medium containing a 1:1 ratio of Waymouth’s MB 
752/1 medium and Ham’s F-12 nutrient mixture (Thermo Fisher Scientific) supplemented 
with 10% FBS (Thermo Fisher Scientific), 100 U/ml penicillin and 100 µg/ml streptomycin 
(Thermo Fisher Scientific) [34, 35]. At least 4 different batches of HAoSMCs were used during the course of this study and each experiment was performed in at least 2 different batches 
of HAoSMCs at different passages, depending on the availability of the cells. HAoSMCs were 
grown to confluence and used in all experiments from passages 4 to 10. HAoSMCs were 
treated for the indicated periods with 2 mM β-glycerophosphate (Sigma Aldrich) [23, 28, 
34, 36-38], 200 ng/ml recombinant human Fibulin-3 protein (R&D Systems) [9, 39] or 10 
µM H2O2 (Sigma Aldrich) [40-42]. Treatment with 10 mM β-glycerophosphate and 1.5 mM 
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CaCl2 (Sigma-Aldrich) for 11 days was used as calcification media for the calcium deposition 
analysis and Alizarin Red staining [43]. Fresh media with agents were added every 2-3 days.
Analysis of calcification
To quantify the calcium deposition, HAoSMCs were decalcified in 0.6 M HCl for 24 hours 
at 4°C. Calcium content in the supernatant was determined by using QuantiChrom Calcium 
assay kit (BioAssay Systems) according to the manufacturer’s protocol. HAoSMCs were lysed 
with 0.1 M NaOH/ 0.1% SDS and protein concentration was measured by the Bradford assay 
(Bio-Rad Laboratories). The results are shown normalized to total protein concentration 
[44]. To visualize calcification, HAoSMCs were fixed with 4% paraformaldehyde and stained 
with 2% Alizarin Red (pH 4.5). The calcified areas are shown as red staining [28].
Alkaline phosphatase (ALPL) activity assay
ALPL activity in HAoSMCs was determined by using the ALP colorimetric assay kit 
(Abcam) according to the manufacturer’s protocol [35]. The results are shown normalized 
to total protein concentration measured by the Bradford assay (Bio-Rad Laboratories).
Antioxidant capacity assay
Total antioxidant capacity of HAoSMCs was measured in the cell lysate by using the 
colorimetric antioxidant assay kit (Cayman Chemical) according to the manufacturer’s protocols. The capacity of the antioxidants in the samples was compared to that of Trolox as standard [28]. The results were normalized to total protein concentration as assessed by the 
Bradford assay (Bio-Rad Laboratories) and to the control group.
Quantitative RT-PCR
Total RNA was isolated from HAoSMCs by using Trizol Reagent (Thermo Fisher Scientific) 
according to the manufacturer’s instructions [45-47]. Reverse transcription of 2 µg RNA was 
performed using oligo(dT)12-18 primers (Thermo Fisher Scientific) and SuperScript III 
Reverse Transcriptase (Thermo Fisher Scientific). Quantitative RT-PCR was performed with 
the iCycler iQTM Real-Time PCR Detection System (Bio-Rad Laboratories) and iQTM Sybr 
Green Supermix (Bio-Rad Laboratories) according to the manufacturer’s instructions. The 
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The specificity of the PCR products was confirmed by analysis of the melting curves. All 
PCRs were performed in duplicate and relative mRNA expression was calculated by the 2-ΔΔCt 
method using GAPDH as internal reference normalized to the control group. 
Western blot analysis
HAoSMCs were lysed with ice-cold IP lysis buffer (Thermo Fisher Scientific) 
supplemented with complete protease and phosphatase inhibitor cocktail (Thermo Fisher 
Scientific) [44]. After centrifugation at 10000 rpm for 5 minutes, the proteins were boiled in 
Roti-Load1 Buffer (Carl Roth GmbH) at 100ºC for 10 min. Equal amounts of proteins were 
separated on SDS-polyacrylamide gels and transferred to PVDF membranes. The membranes 
were incubated overnight at 4°C with primary mouse anti-EFEMP1 antibody (diluted 1:1000, 
sc-33722, Santa Cruz Biotechnology) or rabbit anti-GAPDH antibody (diluted 1:5000, #2118, 
Cell Signaling) and then with secondary anti-mouse HRP-conjugated (diluted 1:1000, Cell 
Signaling) or anti-rabbit HRP-conjugated antibody (diluted 1:1000, Cell Signaling) for 1 hour 
at RT. For loading controls, the membranes were stripped in stripping buffer (Thermo Fisher 
Scientific) at RT for 10 minutes. Antibody binding was detected with ECL detection reagent 
(Thermo Fisher Scientific). Bands were quantiﬁed by using ImageJ software and the results 
are shown as the ratio of total protein to GAPDH normalized to the control group.
Statistics
Data are shown as scatterdot plots and arithmetic means ± SEM. N indicates the number 
of independent experiments performed at different passages of the cells. Normality was 
tested with Shapiro-Wilk test. Non-normal datasets were transformed (log, reciprocal or 
sqrt) prior to statistical testing to provide normality according to Shapiro-Wilk test. Statistical 
testing was performed by one-way Anova followed by Tukey-test for homoscedastic data or 
Games-Howell test for heteroscedastic data. Non-normal data were tested by the Steel-Dwass 
method. Two groups were compared by unpaired two-tailed t-test. P<0.05 was considered 
statistically significant.
Results
To investigate the effects of Fibulin-3 on phosphate-induced vascular calcification, a 
first series of experiments was performed in primary human aortic smooth muscle cells 
(HAoSMCs) following treatment with calcification media without or with additional treatment 
with recombinant human Fibulin-3 protein. As a result, Alizarin Red staining (Fig. 1A) and 
quantification of calcium deposition (Fig. 1B) in HAoSMCs revealed extensive calcification 
following treatment with calcification media, an effect significantly reduced by additional 
treatment with Fibulin-3. As shown in Fig. 1C-G, phosphate treatment significantly up-
regulated ALPL activity and the mRNA expression of osteogenic markers MSX2, CBFA1 and 
ALPL and of chondrogenic marker SOX9 in HAoSMCs, all effects again significantly blunted 
by additional treatment with Fibulin-3. Treatment with Fibulin-3 alone did not significantly 
modify the calcium deposition and osteo-/chondrogenic markers expression in HAoSMCs 
(Fig. 1). Taken together, Fibulin-3 inhibits phosphate-induced osteo-/chondrogenic 
transdifferentiation and calcification of VSMCs in-vitro.
Additional experiments were performed to elucidate the underlying mechanisms of the 
protective effects of Fibulin-3 on VSMC calcification. Phosphate treatment did not significantly 
affect Fibulin-3 (encoded by the EFEMP1 gene) mRNA and protein expression in HAoSMCs 
(Fig. 2). Nonetheless, additional treatment with Fibulin-3 blunted the increased mRNA expression of NOX4 and p22phox (encoded by the CYBA gene) induced by high phosphate 
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conditions in HAoSMCs, two critical components of the superoxide-generating NADH/NADPH 
oxidase system and markers of oxidative stress (Fig. 3A,B). Moreover, Fibulin-3 ameliorated 
the decrease of total antioxidant capacity in phosphate treated HAoSMCs (Fig. 3C). Thus, 
Fibulin-3 inhibits phosphate-induced oxidative stress in HAoSMCs.These effects were paralleled by similar alteration of the oxidative stress downstream 
effectors in HAoSMCs. Phosphate treatment up-regulated the mRNA expression of plasminogen activator inhibitor PAI-1 (Fig. 4A) and of matrix gelatinases MMP2 and MMP9 
(Fig. 4B,C) in HAoSMCs, all effects significantly reduced following additional treatment with Fibulin-3 protein. Furthermore, phosphate treatment induced indicators of apoptosis in 
Fig. 1. Fibulin-3 inhibits phosphate-induced osteoinductive signaling and calcification in HAoSMCs. A. Rep-
resentative original images showing Alizarin red staining in HAoSMCs following treatment for 11 days with 
control or with calcification medium (Calc.) without or with additional treatment with 200 ng/ml recom-
binant human Fibulin-3 protein. The calcified areas are shown as red staining. Images are representative 
for three independent experiments. B. Scatterdot plots and arithmetic means ± SEM (n=6, µg/mg protein) 
of calcium content in HAoSMCs following treatment for 11 days with control or with calcification medium 
(Calc.) without or with additional treatment with 200 ng/ml recombinant human Fibulin-3 protein. C. Scat-
terdot plots and arithmetic means ± SEM (n=4, U/mg protein) of ALPL activity in HAoSMCs following treat-
ment for 7 days with control or with 2 mM β-glycerophosphate (Pi) without or with additional treatment 
with 200 ng/ml recombinant human Fibulin-3 protein. D-G. Scatterdot plots and arithmetic means ± SEM 
(n=6; arbitrary units, a.u.) of MSX2 (D), CBFA1 (E), SOX9 (F) and ALPL (G) relative mRNA expression in 
HAoSMCs following treatment for 24 hours with control or with 2 mM β-glycerophosphate (Pi) without or 
with additional treatment with 200 ng/ml recombinant human Fibulin-3 protein. *(p<0.05), **(p<0.01), 
***(p<0.001) statistically significant vs. control treated HAoSMCs; †(p<0.05), ††(p<0.01), †††(p<0.001) sta-
tistically significant vs. HAoSMCs treated with Calc./Pi alone.
Fig. 2. Fibulin-3 expression is not modi-
fied by phosphate in HAoSMCs. A. Scat-
terdot plots and arithmetic means ± SEM 
(n=6; arbitrary units, a.u.) of EFEMP1 
relative mRNA expression in HAoSMCs 
following treatment for 24 hours with 
control or with 2 mM β-glycerophosphate 
(Pi). B. Representative original Western blots and scatterdot plots and arithmetic 
means ± SEM (n=4; a.u.) of normalized Fibulin-3/GAPDH protein ratio in HAoSMCs following treatment for 
24 hours with control or with 2 mM β-glycerophosphate (Pi).
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HAoSMCs, as shown by an increase in BAX/BCL2 mRNA expression ratio (Fig. 4D). These 
effects were again significantly ameliorated by Fibulin-3 treatment. To further investigate whether inhibition of oxidative stress is responsible for the 
anti-calcific effects of Fibulin-3, low concentrations of H2O2 were added to HAoSMCs as 
an exogenous source of oxidative stress. As shown in Fig. 5, treatment with H2O2 alone 
significantly up-regulated MSX2, CBFA1, SOX9 and ALPL mRNA expression in HAoSMCs to 
similarly high levels as phosphate treatment and aggravated osteo-/chondrogenic markers 
expression in phosphate treated HAoSMCs (Fig. 5A-D) without significantly affecting EFEMP1 
mRNA expression (Fig. 5E). More importantly, addition of H2O2 blocked the protective effects 
of Fibulin-3 on phosphate-induced osteo-/chondrogenic transdifferentiation of HAoSMCs 
(Fig. 5). Thus, the protective effects of Fibulin-3 on phosphate-induced osteo-/chondrogenic 
transdifferentiation of VSMCs are due, at least in part, to inhibition of endogenous oxidative stress. 
Fig. 3. Fibulin-3 attenuates phosphate-induced oxidative stress in HAoSMCs. A,B. Scatterdot plots and 
arithmetic means ± SEM (n=6; arbitrary units, a.u.) of NOX4 (A) and CYBA (B) relative mRNA expression in 
HAoSMCs following treatment for 24 hours with control or with 2 mM β-glycerophosphate (Pi) without or 
with additional treatment with 200 ng/ml recombinant human Fibulin-3 protein. C. Scatter dot plots and 
arithmetic means ± SEM (n=6; a.u.) of normalized total antioxidant capacity of HAoSMCs following treat-
ment for 24 hours with control or with 2 mM β-glycerophosphate (Pi) without or with additional treatment 
with 200 ng/ml recombinant human Fibulin-3 protein. **(p<0.01), ***(p<0.001) statistically significant 
vs. control treated HAoSMCs; †(p<0.05), †††(p<0.001) statistically significant vs. HAoSMCs treated with Pi alone.
Fig. 4. Fibulin-3 inhibits the ex-pression of oxidative stress down-stream effectors during high phos-
phate conditions in HAoSMCs. A-D. 
Scatterdot plots and arithmetic 
means ± SEM (n=6; arbitrary units, 
a.u.) of PAI-1 (A), MMP2 (B) and 
MMP9 (C) relative mRNA expres-sion as well as BAX/BCL2 relative 
mRNA expression ratio (D) in HA-
oSMCs following treatment for 24 
hours with control or with 2 mM 
β-glycerophosphate (Pi) with-out or with additional treatment 
with 200 ng/ml recombinant hu-
man Fibulin-3 protein. *(p<0.05), 
***(p<0.001) statistically signifi-
cant vs. control treated HAoSMCs; 
†(p<0.05), †††(p<0.001) statis-
tically significant vs. HAoSMCs 
treated with Pi alone.
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Discussion
The present study reveals a novel role of Fibulin-3 in the inhibition of osteo-/
chondrogenic transdifferentiation and calcification of VSMCs during hyperphosphatemia in-vitro. Fibulin-3 treatment blunts phosphate-induced oxidative stress, while addition of 
an exogenous source of oxidative stress suppresses the anti-calcific effects of Fibulin-3 in 
VSMCs.Oxidative stress represents the imbalance between antioxidant systems and oxidative 
products [20]. Phosphate up-regulates the expression of NOX4 and CYBA, two critical 
components of the superoxide-generating NADH/NADPH oxidase system [48, 49] and reduces 
total antioxidant capacity of VSMCs. Fibulin-3 supplementation is able to suppress the expression of NADH/NADPH oxidase system components and may, thus, interfere with reactive oxygen species production in VSMCs. In accordance with previous observations [10], Fibulin-3 
treatment is able to block the accumulation of oxidative stress in phosphate treated VSMCs. 
Excessive oxidative stress is involved in the pathogenesis of vascular calcification 
[20, 28-30]. Reactive oxygen species are mediators of CKD-related vascular calcification 
[48, 50]. Similarly, increased NADPH oxidase activity is associated with coronary artery 
calcification in asymptomatic men [49]. Oxidative stress contributes to the progression of 
vascular calcification via active cellular mechanisms by stimulating osteo-/chondrogenic 
transdifferentiation of VSMCs [29, 50]. Accordingly, hydrogen peroxide induces the 
phenotypical transformation of VSMCs into osteoblast-like cells, including up-regulation of 
CBFA1 expression [29] and ALPL activity [30] to facilitate mineral deposition. Conversely, 
Fig. 5. The protective effects of Fibulin-3 on phosphate-induced osteoinduction are blunted by addition of H2O2 as an exogenous source of oxidative stress in HAoSMCs. A-D. Scatterdot plots and arithmetic means 
± SEM (n=6; arbitrary units, a.u.) of MSX2 (A), CBFA1 (B), SOX9 (C) and ALPL (D) relative mRNA expres-
sion in HAoSMCs following treatment for 24 hours with control, 2 mM β-glycerophosphate alone (Pi), 10 
µM H2O2 alone or 2 mM β-glycerophosphate together with 10 µM H2O2 (Pi+H2O2), 200 ng/ml recombinant 
human Fibulin-3 protein (Pi+FBLN3) or 200 ng/ml recombinant human Fibulin-3 protein and 10 µM H2O2 
(Pi+FBLN3+H2O2). ***(p<0.001) statistically significant vs. control treated HAoSMCs; †(p<0.05), ††(p<0.01), 
†††(p<0.001) statistically significant vs. HAoSMCs treated with Pi alone; §§§(p<0.001) statistically signifi-
cant between Pi+FBLN3 and Pi+FBLN3+H2O2 HAoSMCs. E. Scatterdot plots and arithmetic means ± SEM 
(n=6; a.u.) of EFEMP1 relative mRNA expression in HAoSMCs following treatment for 24 hours with control, 
2 mM β-glycerophosphate alone (Pi), 10 µM H2O2 alone or 2 mM β-glycerophosphate together with 10 µM H2O2 (Pi+H2O2).
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antioxidants are able to reduce osteo-/chondrogenic transdifferentiation and calcification 
of VSMCs [51]. The present data shows that Fibulin-3 suppresses the increased expression of osteogenic transcription factors MSX2 and CBFA1 and of chondrogenic transcription factor SOX9 as well as ALPL expression and activity in VSMCs following high phosphate 
treatment. Previous studies similarly show that Fibulin-3 is able to reduce SOX9 expression and to inhibit chondrogenesis in bone marrow-derived mesenchymal stem cells as well as 
differentiation of chondrocytes [52, 53]. 
Downstream effectors of oxidative stress in VSMCs include plasminogen activator 
inhibitor PAI-1 [16, 54] and the matrix metalloproteinases MMP2 and MMP9, also known as 
gelatinases [14-17, 55]. The increased PAI-1 expression, a regulator of VSMCs calcification 
[28, 56], is attenuated by Fibulin-3 during high phosphate conditions. Similarly, Fibulin-3 reduces phosphate-induced MMP2 and MMP9 expression in VSMCs. Gelatinases are essential 
for phenotypical transformation of VSMCs, matrix remodeling and initiation of vascular 
calcification [57, 58] by up-regulation of bone morphogenetic protein-2 (BMP-2) which 
induces the expression of CBFA1 and MSX2 [59]. Furthermore, oxidative stress is able to 
induce apoptosis of VSMCs [60] and apoptosis may promote the initiation and progression 
of vascular calcification [61]. Accordingly, Fibulin-3 is able to inhibit phosphate-induced increase in BAX/BCL2 ratio in VSMCs, a maker of increased apoptosis. The inhibitory effect of Fibulin-3 on phosphate-induced osteogenic and chondrogenic 
markers expression in VSMCs is blunted by additional treatment with low concentrations of hydrogen peroxide. Thus, in the presence of an exogenous source of oxidative stress, 
Fibulin-3 fails to inhibit the osteo-/chondrogenic signaling in VSMCs. Taken together, the present observations suggest that Fibulin-3 may be effective not by interfering with 
oxidative stress-downstream osteoinductive signaling in VSMCs, but rather by interfering with reactive oxygen species production and accumulation of oxidative stress in VSMCs. 
Excessive oxidative stress does not modify Fibulin-3 expression in VSMCs. However, 
oxidation may render Fibulin-3 biologically inactive [1, 2, 62-64]. Further studies are clearly 
required to elucidate whether Fibulin-3 function is affected by calcific conditions in VSMCs. 
Nonetheless, the current observations suggest that Fibulin-3 supplementation reduces 
osteo-/chondrogenic signaling in VSMCs and, thus, vascular calcification, effects involving inhibition of endogenous oxidative stress.
In addition, other mechanisms may contribute to the anti-calcific effects of Fibulin-3 in the vascular tissue. Fibulin-3 may hinder extracellular matrix remodeling and elastin 
degradation [4, 5, 61, 65, 66]. Furthermore, Fibulin-3 may interfere with various intracellular 
signaling pathways [7-9] in vascular calcification. Fibulin-3 was previously shown to 
be an inhibitor of TGF-β-dependent signaling [9], a key intracellular pathway in osteo-/
chondrogenic transdifferentiation of VSMCs [67, 68]. However, addition of Fibulin-3 failed to 
suppress the TGF-β-dependent osteoinductive signaling in VSMCs (data not shown).
Despite the finding that phosphate did not directly affect Fibulin-3 expression in VSMCs, the present observations suggest that Fibulin-3 may reduce the progression of vascular 
calcification in conditions of hyperphosphatemia such as CKD [21, 27]. In these patients, oxidative stress is further associated with increased cardiovascular and all-cause mortality [18-20] and thus, Fibulin-3 may have overall protective effects in systemic changes during disease progression. However, Fibulin-3 may promote neoplastic growth in some tumors [69, 
70]. Also, tumor suppressive properties of Fibulin-3 were described [71]. These observations warrant caution and further investigations of a possible safe further translation of Fibulin-3 
treatment in CKD patients [72]. 
In theory, Fibulin-3 may be effective in reducing vascular calcification in other 
pathologies associated with oxidative stress such as diabetes mellitus [73, 74] or aging [28, 
75]. Fibulin-3 expression is decreased with aging [52] and Fibulin-3 deficiency in mice leads 
to early onset of aging-associated phenotypes [76]. Further studies are necessary to confirm 
the potential benefits of Fibulin-3 in these conditions.
In conclusion, Fibulin-3 reduces phosphate-induced osteo-/chondrogenic 
transdifferentiation of VSMCs and, thus, vascular calcification by inhibiting endogenous 
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oxidative stress. The present observations reveal that up-regulation or supplementation of 
Fibulin-3 may be beneficial in reducing the progression of vascular calcification during high 
phosphate conditions such as CKD.
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